JLE

European Journal of Dermatology

MENU

Acral lentiginous melanoma with HER2/ErbB2 amplification Volume 31, numéro 4, July-August 2021

Illustrations


  • Figure 1
Auteurs
1 Department of Pathology, Lyon University Hospital, Hospices Civils de Lyon, Hôpital Lyon-Sud, Lyon, France
2 Department of Dermatology, Hôpitaux Drôme Nord, Romans-sur-Isère, France
3 Department of Dermatology, Lyon University Hospital, Hospices Civils de Lyon, Hôpital Lyon-Sud, Lyon, France
4 Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
5 Department of Biochemistry and Molecular Biology, Lyon University Hospital, Hospices Civils de Lyon, Hôpital Lyon-Sud, Lyon, France
6 Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM1052, CNRS5286, Lyon, France

Acral lentiginous melanoma (ALM) is a rare melanoma on the palms, soles and nail beds with a worse prognosis compared to other subtypes [1]. Its genetic landscape is characterized by a low a tumour mutational burden rather than the classic UV radiation signature of cutaneous melanomas. Only 15% of ALM harbour a BRAF V600E mutation, compared to 45% of other subtypes [2]. NRAS mutations (15% of cases) and KIT mutations or amplifications (15-40% of cases) are also reported [2]. These driver alterations [...]